Health-related Quality of Life and Mortality in Male Patients with Chronic Obstructive Pulmonary Disease

Domingo‐Salvany, Antònia; Lamarca, Rosa; Ferrer, Montse; Garcia‐Aymerich, Judith; Alonso, Jordi; Félez, M A; Khalaf, Ahmad Taha; Marrades, Ramón; Monsó, Eduard; Serra-Batllés, Joan; Antó, Josep M.

doi:10.1164/rccm.2112043

Cited by 362 publications

(240 citation statements)

References 24 publications

Supporting

Mentioning

216

Contrasting

Unclassified

Order By: Relevance

“…5,8,11,24 The relatively low mortality rate is likely due to the fact that patients were recruited from outpatient clinics, not from hospitals settings 25 where mortality rates can be up to 49% at 2 years. 26 FEV 1% had the strongest association with mortality in our study, a relationship that has been observed in other studies.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, to improve the use of these predictive models, they need to include variables that are easily gathered in busy clinical practices. Although health-related quality of life (HRQoL) has been shown to be an independent predictor of mortality in patients with COPD, 11 not all HRQoL measurement instruments appear to behave in the same way. 12 Few studies have compared St. George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Questionnaire (CRQ) for assessing prognosis in COPD patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Predictors of Mortality in Patients with Stable COPD

et al. 2008

View full text Add to dashboard Cite

OBJECTIVES:To determine which easily available clinical factors are associated with mortality in patients with stable COPD and if health-related quality of life (HRQoL) provides additional information. DESIGN:Five-year prospective cohort study. SETTING:Five outpatient clinics of a teaching hospital.PARTICIPANTS: Six hundred stable COPD patients recruited consecutively. MEASUREMENTS:The variables were age, FEV 1% , dyspnea, previous hospital admissions and emergency department visits for COPD, pack-years of smoking, comorbidities, body mass index, and HRQoL measured by Saint George's Respiratory Questionnaire (SGRQ), Chronic Respiratory Questionnaire (CRQ), and ShortForm 36 (SF-36). Logistic and Cox regression models were used to assess the influence of these variables on mortality and survival.RESULTS: FEV 1% (OR: 0.62, 95% CI 0.5 to 0.75), dyspnea (OR 1.92, 95% CI 1.2 to 3), age (OR 2.41, 95% CI 1.6 to 3.6), previous hospitalization due to COPD exacerbations (OR 1.53, 1.2 to 2) and lifetime pack-years (OR 1.15, 95% CI 1.1 to 1.2) were independently related to respiratory mortality. Similarly, these factors were independently related to all-cause mortality with dyspnea having the strongest association (OR 1.54, 95% CI 1.1 to 2.2). HRQoL was an independent predictor of respiratory and all-cause mortality only when dyspnea was excluded from the models, except scores on the SGRQ were associated with all-cause mortality with dyspnea in the model. CONCLUSIONS:Among patients with stable COPD, FEV 1% was the main predictor of respiratory mortality and dyspnea of all-cause mortality. In general, HRQoL was not related to mortality when dyspnea was taken into account, and CRQ and SGRQ behaved in similar ways regarding mortality.KEY WORDS: chronic obstructive pulmonary disease; mortality; healthrelated quality of life.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Predictors of Mortality in Patients with Stable COPD

et al. 2008

View full text Add to dashboard Cite

show abstract

“…COPD is highly prevalent [2], responsible for 2.7 million deaths globally in 2000 [3], and associated with increased morbidity and mortality as well as a reduced quality of life [4,5]. The 1997…”

Section: Introductionmentioning

confidence: 99%

Aclidinium bromide provides long-acting bronchodilation in patients with COPD

Chanez¹,

Burge²,

Dahl³

et al. 2010

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

Aclidinium bromide is a novel, long-acting, muscarinic antagonist in phase III development for the maintenance treatment of COPD. This phase IIb study investigated the efficacy and safety of aclidinium for the treatment of moderate to severe COPD to establish the optimal dose for phase III studies. A total of 464 patients with moderate to severe stable COPD were randomised to double-blind, once-daily treatment with aclidinium (25, 50, 100, 200, or 400 μg), placebo, or openlabel tiotropium (18 μg) for 4 weeks. Spirometric measurements were performed at 22-24 h after the first dose and then at weekly intervals, and from 0.5-6 h post-dose on day 1 and day 29. Compared with placebo, aclidinium 200 μg and 400 μg significantly increased trough FEV 1 on day 29 versus baseline. During the first 6 h post-dose, the bronchodilatory effect of aclidinium (all doses) on day 1 was comparable to that on day 29. Time to peak FEV 1 was 3 h for aclidinium 100-400 μg. Aclidinium was well tolerated, with no dose-dependent effect on ECG, laboratory parameters, or adverse events. The incidence of AEs was generally comparable to placebo. Aclidinium produced sustained bronchodilation over 24 h and was well tolerated during this short-term study. Based on these data, aclidinium 200 μg was selected as the investigational dose for future clinical trials in COPD.

show abstract

“…The activity component is the strongest predictor of death among the four scores of the SGRQ: Symptom, Activity, Impact, and Total score (ref. 24 ). It is difficult to select the most accurate activity scoring system as they are not widely used in COPD.…”

Section: Components Of Copd Prognostic Scorementioning

confidence: 99%

Chronic obstructive pulmonary disease prognostic score: A new index

Horita¹,

Koblížek²,

Plutinsky³

et al. 2016

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Background. The evaluation of chronic obstructive pulmonary disease (COPD) has been shifting from spirometry to focus on the patients' overall health. Despite the existence of many COPD prognostic scales, there remains a large gap for improvement, in particular a scale that incorporates the current focus on overall health. Methods. We proposed a new prognostic scale (the COPD Prognostic Score) through discussion among the authors based on published studies. Validation was retrospective, using data from the National Emphysema Treatment Trial. Results. The scores ranged from 0-16, where 16 indicated the poorest prognosis. We assigned 4 points each for forced expiratory volume in one second (%predicted), the modified Medical Research Council dyspnea scale, and age; 2 points for the hemoglobin level; and one point each for decreased activity and respiratory emergency admission in the last two years. The validation cohort included 607 patients and consisted of 388 men (73.9%) and 219 women (36.1%), mean age 67 ± 6 years and an average forced expiratory volume in one second (% predicted) of 27 ± 7%. A one-point increase in the score was associated with increased all-cause death, with a hazard ratio of 1.28 (95%CI: 1.21-1.36. P < 0.001). The areas under the receiver operating characteristic curves for two-year and five-year all-cause death for the new scale were 0.72 and 0.66, respectively. These values were higher than those given by the body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index and age, dyspnea, airway obstruction (ADO) index. Conclusion. The preliminary validation for a new COPD prognostic scale: the COPD Prognostic Score was developed with promising results thus far. Above mentioned 16-point score accurately predicted 2-year and 5-year all-cause mortality among subjects who suffered from severe and very severe COPD.

show abstract

Health-related Quality of Life and Mortality in Male Patients with Chronic Obstructive Pulmonary Disease

Cited by 362 publications

References 24 publications

Predictors of Mortality in Patients with Stable COPD

Predictors of Mortality in Patients with Stable COPD

Aclidinium bromide provides long-acting bronchodilation in patients with COPD

Chronic obstructive pulmonary disease prognostic score: A new index

Contact Info

Product

Resources

About